Rapid diagnostic testing (RDT) can provide prompt, accurate identification of infectious organisms and be a key component of antimicrobial stewardship (AMS) programs. However, cost can be prohibitive, particularly in less resource-replete settings. Despite the increasing availability and scope of RDT methods, there is currently no global or regional consensus on what constitutes an RDT. Across Asia Pacific, more data is needed on RDT use within AMS, focusing on the impact on antimicrobial usage, patient morbidity and mortality, and cost effectiveness. By addressing these issues and developing consensus-based statements to guide clinical practice, the outcomes of AMS programs will improve across the region.

The Society for Healthcare Epidemiology of America (SHEA)

Cambridge University Press
November 30, 2021